JP2009519915A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519915A5
JP2009519915A5 JP2008544833A JP2008544833A JP2009519915A5 JP 2009519915 A5 JP2009519915 A5 JP 2009519915A5 JP 2008544833 A JP2008544833 A JP 2008544833A JP 2008544833 A JP2008544833 A JP 2008544833A JP 2009519915 A5 JP2009519915 A5 JP 2009519915A5
Authority
JP
Japan
Prior art keywords
vaccine composition
peptide
amyloid
disease
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008544833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519915A (ja
JP5249043B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/011861 external-priority patent/WO2007068411A2/en
Publication of JP2009519915A publication Critical patent/JP2009519915A/ja
Publication of JP2009519915A5 publication Critical patent/JP2009519915A5/ja
Application granted granted Critical
Publication of JP5249043B2 publication Critical patent/JP5249043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008544833A 2005-12-12 2006-12-08 治療ワクチン Active JP5249043B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05027091.7 2005-12-12
EP05027091 2005-12-12
EP06009098 2006-05-02
EP06009098.2 2006-05-02
PCT/EP2006/011861 WO2007068411A2 (en) 2005-12-12 2006-12-08 Therapeutic vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013025108A Division JP2013126993A (ja) 2005-12-12 2013-02-13 治療ワクチン

Publications (3)

Publication Number Publication Date
JP2009519915A JP2009519915A (ja) 2009-05-21
JP2009519915A5 true JP2009519915A5 (cg-RX-API-DMAC7.html) 2010-01-28
JP5249043B2 JP5249043B2 (ja) 2013-07-31

Family

ID=37836865

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008544833A Active JP5249043B2 (ja) 2005-12-12 2006-12-08 治療ワクチン
JP2013025108A Withdrawn JP2013126993A (ja) 2005-12-12 2013-02-13 治療ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013025108A Withdrawn JP2013126993A (ja) 2005-12-12 2013-02-13 治療ワクチン

Country Status (23)

Country Link
US (2) US7807175B2 (cg-RX-API-DMAC7.html)
EP (2) EP2380588B1 (cg-RX-API-DMAC7.html)
JP (2) JP5249043B2 (cg-RX-API-DMAC7.html)
KR (2) KR101152557B1 (cg-RX-API-DMAC7.html)
CN (1) CN101330923B (cg-RX-API-DMAC7.html)
AR (1) AR058327A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006326283B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0619747B8 (cg-RX-API-DMAC7.html)
CA (1) CA2633399C (cg-RX-API-DMAC7.html)
CR (1) CR9994A (cg-RX-API-DMAC7.html)
DK (1) DK1959991T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP088531A (cg-RX-API-DMAC7.html)
ES (2) ES2551604T3 (cg-RX-API-DMAC7.html)
IL (1) IL191397A (cg-RX-API-DMAC7.html)
MA (1) MA30252B1 (cg-RX-API-DMAC7.html)
MY (1) MY181173A (cg-RX-API-DMAC7.html)
NO (1) NO346055B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ568384A (cg-RX-API-DMAC7.html)
RU (2) RU2440824C2 (cg-RX-API-DMAC7.html)
SG (1) SG172617A1 (cg-RX-API-DMAC7.html)
TW (1) TWI537000B (cg-RX-API-DMAC7.html)
WO (1) WO2007068411A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200804918B (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
WO2010059253A2 (en) 2008-11-24 2010-05-27 Massachusets Institute Of Technology Methods and compositions for localized agent delivery
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
KR100929372B1 (ko) * 2009-05-22 2009-12-02 고려대학교 산학협력단 아밀로이드 베타 단편을 유효성분으로 포함하는 돌연변이 sod1에 의한 als 예방 및 치료용 조성물
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
SG184127A1 (en) 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
ES2734552T3 (es) 2010-04-16 2019-12-10 Ac Immune Sa Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
US10654807B2 (en) * 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) * 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
IL301919A (en) * 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
AU2016305087B2 (en) 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018081085A1 (en) * 2016-10-25 2018-05-03 The Regents Of The University Of California Methods of diagnosis and treatment of alzheimer's disease
WO2018204302A1 (en) 2017-05-01 2018-11-08 Vanderbilt University Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN108037277A (zh) * 2017-12-07 2018-05-15 中国兽医药品监察所 一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
HK1049279A1 (zh) * 1999-11-29 2003-05-09 Neurochem (International) Limited 预防及治疗阿尔茨海默病(早老性痴呆)及淀粉样蛋白有关的病之疫苗
DE10003992A1 (de) * 2000-01-29 2001-08-09 Bosch Gmbh Robert Sensoranordnung
WO2002021141A2 (en) * 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
WO2003092700A1 (en) * 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates, and methods of use thereof
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7884188B2 (en) * 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
WO2005012330A2 (en) * 2003-07-30 2005-02-10 Brigham And Women's Hospital, Inc. AMYLOID β-PEPTIDE AND METHODS OF USE
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties

Similar Documents

Publication Publication Date Title
RU2008128133A (ru) Терапевтическая вакцина
CN101420983B (zh) 包含超分子抗原构建体的组合物和方法
KR20110030554A (ko) 항아밀로이드 면역원성 조성물, 방법 및 용도
EP2659908A1 (en) Compositions
US20060147417A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
US20120171239A1 (en) Immunogenic Conjugates for Producing Immune Responses to Drugs of Abuse and Methods of Use
JPH05506234A (ja) ワクチン組成物
WO1996010423A1 (en) COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF
DK2465533T3 (en) Methods and compositions comprising supramolecular constructs
JP2007527870A5 (cg-RX-API-DMAC7.html)
HK1172260B (en) Methods and compositions comprising supramolecular constructs
HK1130698B (en) Methods and compositions comprising supramolecular constructs